Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) EVP Suresh K. Durgam sold 7,344 shares of the company’s stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $45.04, for a total transaction of $330,773.76. Following the transaction, the executive vice president now owns 23,104 shares in the company, valued at $1,040,604.16. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Intra-Cellular Therapies Price Performance
Shares of ITCI stock opened at $45.31 on Wednesday. The company has a market capitalization of $4.32 billion, a P/E ratio of -16.66 and a beta of 1.13. The company’s 50-day simple moving average is $48.16 and its two-hundred day simple moving average is $49.20. Intra-Cellular Therapies, Inc. has a one year low of $42.01 and a one year high of $66.00.
Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) last issued its earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.17. Intra-Cellular Therapies had a negative net margin of 102.37% and a negative return on equity of 35.88%. The business had revenue of $87.87 million for the quarter, compared to the consensus estimate of $86.97 million. During the same period in the prior year, the firm earned ($1.05) EPS. The company’s revenue for the quarter was up 242.3% compared to the same quarter last year. On average, research analysts expect that Intra-Cellular Therapies, Inc. will post -2.42 EPS for the current fiscal year.
Hedge Funds Weigh In On Intra-Cellular Therapies
Analysts Set New Price Targets
ITCI has been the topic of several analyst reports. Mizuho cut their price target on shares of Intra-Cellular Therapies from $72.00 to $66.00 in a report on Friday, March 3rd. Needham & Company LLC reiterated a “buy” rating and set a $70.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, March 1st. JPMorgan Chase & Co. cut their price target on shares of Intra-Cellular Therapies from $59.00 to $58.00 and set an “overweight” rating on the stock in a report on Thursday, March 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $83.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, February 1st. Finally, Royal Bank of Canada cut their price target on shares of Intra-Cellular Therapies from $75.00 to $71.00 and set an “outperform” rating on the stock in a report on Thursday, March 2nd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $69.40.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS.
- Get a free copy of the StockNews.com research report on Intra-Cellular Therapies (ITCI)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.